C4X Discovery Holdings plc: Half-year results for the six months ended 31 January 2023
Up to $402 million AstraZeneca deal for NRF2 Activator programme; Third global out-licensing deal executed
- Up to $402 million AstraZeneca deal for NRF2 Activator programme; Third global out-licensing deal executed
MANCHESTER, United Kingdom, April 26, 2023 (GLOBE NEWSWIRE) -- C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces its half-year results for the six months ended 31 January 2023. - "I'm excited that following a review of our expertise and previous successes, our strategy is now focused on treatments for immuno-inflammatory diseases.
- Indivior's Phase 1 multiple ascending dose clinical trial of C4XD's oral Orexin-1 receptor antagonist, C4X_3256 (INDV-2000), for substance use disorder is ongoing.
- C4XD signed an exclusive worldwide licensing agreement with AstraZeneca in November 2022, worth up to $402 million, for its NRF2 Activator programme.